14th March 2022 | Pharma Updates
USFDA makes three observations on Zydus' Jarod manufacturing unit
Following an examination of its Jarod (Vadodara) manufacturing facility, Zydus Lifesciences got three observations from the USFDA.
How advanced medical device technology is enhancing India's health infrastructure
Covid-19 has sped the country’s shift to a more advanced technology-based medical device sector, which is helping to improve overall health infrastructure as well as patient care quality.
FDA approved AstraZeneca-Lynparza Merck's to treat early-stage breast cancer
Lynparza, a medication developed by AstraZeneca, for patients with a kind of genetically modified high-risk earlystage breast cancer known as BRCAmutated HER2-negative.
Macleods Pharmaceuticals recalls products in the United States
According to a USFDA notice, Macleods Pharmaceuticals is recalling two medications in the US market due to deviations from established manufacturing criteria.
GeoVax vaccine, which targets the virus in two locations, shows potential
In a small pilot study, an experimental vaccine produced by GeoVax Labs Inc succeeds in stimulating the development of antibodies that target two separate locations on the virus and has been forwarded to mid-stage clinical trials.
InnoCare Announces Acceptance of Orelabrutinib Supplemental NDA in China
China National Medical Products Administration’s (NMPA) CDE has accepted the sNDA for the Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of relapsed or refractory Waldenström’s Macroglobulinemia (R/R WM).
WHO is evaluating when and how to declare the end of the Covid emergency
Over two years after the virus’s emergence, the World Health Organization has begun deliberating on the criteria for declaring the global COVID-19 epidemic over.
Timing of cancer drugs may render COVID-19 vaccines ineffective
Stanford Medicine researchers have found that certain cancer patients who had rituximab or similar medications respond poorly or not at all to subsequent COVID-19 mRNA vaccines.
GAVRETO has received NMPA approval, according to CStone
GAVRETO is the first and only selective RET inhibitor approved in China for the treatment of RETmutant medullary thyroid carcinoma (MTC) and RET fusionpositive thyroid cancer (TC).
Creyon Bio receives funding for a fresh approach to AI and genetic medicine research
Creyon Bio introduce artificial intelligence technologies for drug development & says that their method can give enough safety and toxicity to allow a therapy to avoid the animal testing prior to clinical trials.